



Clinical trial results:

A Double-Blind, Placebo-Controlled, Randomized, Two-stage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease (DKD) Who Have Residual Macroalbuminuria Despite Treatment with an Inhibitor of the Renin-Angiotensin System.

Summary

EudraCT number	2012-005093-54
Trial protocol	DK FR
Global end of trial date	12 June 2015

Results information

Result version number	v1 (current)
This version publication date	26 June 2016
First version publication date	26 June 2016

Trial information

Trial identification

Sponsor protocol code	CV202-010
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01752985
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Bristol-Myers Squibb International Corporation, Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 June 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 June 2015
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective of the study was to determine efficacy of BMS-813160 in reducing urinary albumin excretion as measured by the urine albumin-to-creatinine ratio (UACR) during 12 weeks of double-blinded treatment in subjects with type 2 diabetes mellitus and diabetic kidney disease (DKD) and persistent baseline macro-albuminuria on the background of stable angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy:

Subjects remained on their background treatment regimen with an oral ACEI or ARB that has been established prior to their enrollment.

Evidence for comparator: -

Actual start date of recruitment	03 April 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 60
Country: Number of subjects enrolled	United States: 209
Country: Number of subjects enrolled	Denmark: 17
Country: Number of subjects enrolled	France: 33
Worldwide total number of subjects	319
EEA total number of subjects	50

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	172
From 65 to 84 years	147
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 57 centers in 4 countries.

Pre-assignment

Screening details:

Out of 319 subjects who were enrolled, 110 subjects completed the screening period. Reasons for 209 subjects for not completing the screening periods were: Subjects did not meet study criteria-178, Subjects withdrew consent-8, Lost to follow-up-1, Administrative reason by Sponsor-6, Subject request to discontinue treatment-1, and other reasons-15.

Period 1

Period 1 title	Pretreatment / Screening Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	All Subjects
-----------	--------------

Arm description:

Subjects with type 2 diabetes mellitus were enrolled and screened for 27 days.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 1	All Subjects
Started	319
Completed	110
Not completed	209
Subject request to discontinue treatment	1
Consent withdrawn by subject	8
other reasons	15
Lost to follow-up	1
Subject no longer meets study criteria	178
Administrative reason by sponsor	6

Period 2

Period 2 title	Lead-in Period
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Arm title	Placebo matching with BMS-813160
------------------	----------------------------------

Arm description:

Subjects received BMS-813160 matching placebo capsules, orally, twice daily for 2 weeks.

Arm type	Placebo
Investigational medicinal product name	BMS-813160 matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered with BMS-813160 matching placebo capsules, twice daily for 2 weeks.

Number of subjects in period 2^[1]	Placebo matching with BMS-813160
Started	98
Completed	89
Not completed	9
Adverse event, non-fatal	2
Lost to follow-up	2
Subject no longer meets study criteria	3
Administrative reason	2

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Out of 110 subjects who completed the Screening period, 98 subjects entered the Lead-in period. 12 subjects did not entered the Lead-in period.

Period 3

Period 3 title	Treatment Period
Is this the baseline period?	Yes ^[2]
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	BMS-813160 150 mg QD
------------------	----------------------

Arm description:

Subjects received BMS-813160 150 mg, capsule, orally along with matching placebo in Ante Meridiem (AM) and 2 Placebo matching with BMS-813160, capsules, orally in Post Meridiem (PM) for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	BMS-813160
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Subjects were administered with BMS-813160 150 mg capsule once daily in AM for 12 weeks.

Investigational medicinal product name	Placebo matching with BMS-813160
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

Placebo capsules matching with BMS-813160 were administered orally (1 in AM and 2 in PM) for 12 weeks.

Arm title	BMS-813160 300 mg BID
------------------	-----------------------

Arm description:

Subjects received 2 BMS-813160 150 mg capsules, orally, twice daily (2*150 in AM and 2*150 in PM) for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	BMS-813160
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

2 BMS-813160 150-mg capsules were administered orally twice daily in AM and PM (Total daily dose of 600 mg) for 12 weeks.

Arm title	Placebo
------------------	---------

Arm description:

Subjects received BMS-813160 matching placebo capsules, orally, twice daily in AM and PM for 12 weeks.

Arm type	Placebo
Investigational medicinal product name	BMS-813160 matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

2 BMS-813160 matching placebo capsules were administered twice daily in AM and PM for 12 weeks.

Notes:

[2] - Period 1 is not the baseline period. It is expected that period 1 will be the baseline period.

Justification: Subjects were enrolled and screened to enter into a 2-week placebo lead-in period before they entered into the treatment period.

Number of subjects in period 3[3][4]	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo
Started	29	30	29
Completed	25	27	24
Not completed	4	3	5
Subject request to discontinue treatment	1	-	1
Consent withdrawn by subject	1	1	-
Adverse event, non-fatal	2	1	2
Lost to follow-up	-	-	1
Subject no longer meets study criteria	-	1	1

Notes:

[3] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: Out of 319 subjects enrolled worldwide, 98 subjects entered in the Lead-in period. Out of 89 subjects who completed the Lead-in period, 88 subjects entered in the treatment period (baseline period).

[4] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Out of 89 subjects who completed the Lead-in period, 88 subjects entered the Treatment period. One subject did not enter the Treatment period.

Period 4

Period 4 title	Follow-up Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	BMS-813160 150 mg QD

Arm description:

Subjects were followed up for 4 weeks after receiving BMS-813160 150 mg, capsule, orally along with matching placebo in Ante Meridiem (AM) and 2 Placebo matching with BMS-813160, capsules, orally in Post Meridiem (PM) for 12 weeks.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Arm title	BMS-813160 300 mg BID
------------------	-----------------------

Arm description:

Subjects were followed up for 4 weeks after receiving 2 BMS-813160 150 mg capsules, orally, twice daily (2*150 in AM and 2*150 in PM) for 12 weeks.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Arm title	Placebo
------------------	---------

Arm description:

Subjects were followed up for 4 weeks after receiving BMS-813160 matching placebo capsules, orally, twice daily in AM and PM for 12 weeks.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 4	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo
Started	25	27	24
Completed	28	27	26
Joined	3	0	2
Re-joined for follow-up	3	-	2

Baseline characteristics

Reporting groups

Reporting group title	BMS-813160 150 mg QD
Reporting group description: Subjects received BMS-813160 150 mg, capsule, orally along with matching placebo in Ante Meridiem (AM) and 2 Placebo matching with BMS-813160, capsules, orally in Post Meridiem (PM) for 12 weeks.	
Reporting group title	BMS-813160 300 mg BID
Reporting group description: Subjects received 2 BMS-813160 150 mg capsules, orally, twice daily (2*150 in AM and 2*150 in PM) for 12 weeks.	
Reporting group title	Placebo
Reporting group description: Subjects received BMS-813160 matching placebo capsules, orally, twice daily in AM and PM for 12 weeks.	

Reporting group values	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo
Number of subjects	29	30	29
Age categorical Units: Subjects			
<65 years	14	17	17
>=65 years	15	13	12
Age continuous Units: years			
arithmetic mean	63.9	60.2	60.6
standard deviation	± 9.58	± 8.31	± 11.52
Gender categorical Units: Subjects			
Female	2	7	8
Male	27	23	21
Urinary Albumin-to-Creatinine Ratio (UACR)			
Here number of subjects evaluated for each arms are 29, 28, 28 respectively.			
Units: Milligrams/grams			
arithmetic mean	997.94	944.98	1052.99
standard deviation	± 657.367	± 670.313	± 719.969

Reporting group values	Total		
Number of subjects	88		
Age categorical Units: Subjects			
<65 years	48		
>=65 years	40		
Age continuous Units: years			
arithmetic mean			
standard deviation	-		

Gender categorical			
Units: Subjects			
Female	17		
Male	71		
Urinary Albumin-to-Creatinine Ratio (UACR)			
Here number of subjects evaluated for each arms are 29, 28, 28 respectively.			
Units: Milligrams/grams			
arithmetic mean			
standard deviation	-		

End points

End points reporting groups

Reporting group title	All Subjects
Reporting group description: Subjects with type 2 diabetes mellitus were enrolled and screened for 27 days.	
Reporting group title	Placebo matching with BMS-813160
Reporting group description: Subjects received BMS-813160 matching placebo capsules, orally, twice daily for 2 weeks.	
Reporting group title	BMS-813160 150 mg QD
Reporting group description: Subjects received BMS-813160 150 mg, capsule, orally along with matching placebo in Ante Meridiem (AM) and 2 Placebo matching with BMS-813160, capsules, orally in Post Meridiem (PM) for 12 weeks.	
Reporting group title	BMS-813160 300 mg BID
Reporting group description: Subjects received 2 BMS-813160 150 mg capsules, orally, twice daily (2*150 in AM and 2*150 in PM) for 12 weeks.	
Reporting group title	Placebo
Reporting group description: Subjects received BMS-813160 matching placebo capsules, orally, twice daily in AM and PM for 12 weeks.	
Reporting group title	BMS-813160 150 mg QD
Reporting group description: Subjects were followed up for 4 weeks after receiving BMS-813160 150 mg, capsule, orally along with matching placebo in Ante Meridiem (AM) and 2 Placebo matching with BMS-813160, capsules, orally in Post Meridiem (PM) for 12 weeks.	
Reporting group title	BMS-813160 300 mg BID
Reporting group description: Subjects were followed up for 4 weeks after receiving 2 BMS-813160 150 mg capsules, orally, twice daily (2*150 in AM and 2*150 in PM) for 12 weeks.	
Reporting group title	Placebo
Reporting group description: Subjects were followed up for 4 weeks after receiving BMS-813160 matching placebo capsules, orally, twice daily in AM and PM for 12 weeks.	

Primary: Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment with BMS-813160

End point title	Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment with BMS-813160 ^[1]
End point description: The presence of albumin in the urine (macroalbuminuria) is a marker of kidney disease. Albumin and creatinine concentrations were obtained from spot urine samples. UACR was calculated as the geometric mean of two first-morning void urine UACR measurements with samples collected on two separate occasions within a 4-day period. The analysis was performed in all the subjects who received any study drug. Here, 'n' signifies evaluable subjects for specified categories in respective treatment arms.	
End point type	Primary
End point timeframe: Baseline, Weeks 2, 4, 8, 12, and 16 (Follow-up)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive summary statistics were planned for this outcome measure.

End point values	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	29	30	29	
Units: Percent Change				
arithmetic mean (standard deviation)				
Week 2 (n=28, 27, 28)	5.78 (± 48.994)	3.79 (± 62.795)	2.05 (± 30.771)	
Week 4 (n=28, 26, 28)	18.43 (± 62.661)	5.81 (± 83.274)	1.46 (± 40.051)	
Week 8 (n=26, 26, 26)	19.49 (± 65.381)	9.87 (± 56.557)	5.68 (± 43.659)	
Week 12 (n=22, 26, 24)	6.91 (± 56.666)	29.16 (± 78.69)	8.91 (± 54.025)	
Week 16 (n=26, 24, 23)	0.97 (± 61.72)	20.63 (± 85.578)	23.77 (± 70.411)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Out-of-Range Electrocardiogram (ECG) Interval

End point title	Number of Subjects With Out-of-Range Electrocardiogram (ECG) Interval
-----------------	---

End point description:

12-lead ECGs were performed before and 1 hour after dosing at Weeks 0, 2 and 4. ECGs were recorded after the subject has been supine for at least 5 minutes. The PR interval was defined as the beginning of the P wave to the beginning of the QRS complex, and represents the time taken by electrical impulse to travel from the sinus node through the atrioventricular (AV) node. The QRS complex represented the rapid depolarization of the right and left ventricles. The QT interval was defined as the time from the start of the Q wave to the end of the T wave, and represents the time taken for ventricular depolarization and repolarization. Subjects were evaluated for abnormal ECG intervals. Criteria's for abnormality were PR >200, QRS >120, QT >500, QTcF >450, Change From Baseline >30 milliseconds (msec). The analysis was performed in all the subjects who received any study drug.

End point type	Secondary
End point timeframe:	
Baseline up to Week 16	

End point values	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	29	30	29	
Units: Subjects				
PR >200 msec	8	8	4	
QRS >120 msec	3	3	3	
QT >500 msec	0	1	0	
QTcF >450 msec	7	5	6	
Change from baseline in QT >30 msec	8	6	4	
Change from baseline in QTcF >30 msec	4	3	1	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With On-treatment Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), and Who Died (Treatment Period)

End point title	Number of Subjects With On-treatment Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), and Who Died (Treatment Period)
-----------------	---

End point description:

An AE is any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, or a congenital anomaly, or a medically important event. The analysis was performed in all the subjects who received any study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Treatment Period: From initiation of dosing up to 12 weeks of study treatment

End point values	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	29	30	29	
Units: Subjects				
AEs	17	15	11	
AEs Leading to Discontinuation	2	1	2	
SAEs	3	3	1	
Death	0	1	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Trough Observed Plasma Concentration (C_{trough}) of BMS-813160

End point title	Trough Observed Plasma Concentration (C _{trough}) of BMS-813160
-----------------	---

End point description:

C_{trough} is the minimum estimated plasma concentration at steady state. The analysis was planned to be performed in the Pharmacokinetic (PK) analysis set which included all subjects who receive a dose of study drug and have adequate PK concentration-time data.

End point type	Secondary
End point timeframe:	
Pre-dose at Week 2, 4, 8, 12 and 0.5, 1, 2, 4, and 6 hours post-dose at Week 12	

End point values	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[2]	0 ^[3]	0 ^[4]	
Units: µg/mL				
geometric mean (geometric coefficient of variation)	()	()	()	

Notes:

[2] - Data were not analysed due to the termination of development of BMS-813160.

[3] - Data were not analysed due to the termination of development of BMS-813160.

[4] - Data were not analysed due to the termination of development of BMS-813160.

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under The Plasma Concentration-Time Curve From Time Zero to 6 Hours Post-Dose [AUC(0-6 h)]

End point title	Area Under The Plasma Concentration-Time Curve From Time Zero to 6 Hours Post-Dose [AUC(0-6 h)]
-----------------	---

End point description:

AUC(0-6 h) is the area under the plasma concentration-time curve from pre-dose (0 h) to 6 h post-dose. The analysis was planned to be performed in the Pharmacokinetic (PK) analysis set which included all subjects who receive a dose of study drug and have adequate PK concentration-time data.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Week 12

End point values	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[5]	0 ^[6]	0 ^[7]	
Units: µg/mL				
geometric mean (geometric coefficient of variation)	()	()	()	

Notes:

[5] - Data were not analysed due to the termination of development of BMS-813160.

[6] - Data were not analysed due to the termination of development of BMS-813160.

[7] - Data were not analysed due to the termination of development of BMS-813160.

Statistical analyses

No statistical analyses for this end point

Secondary: Renal Clearance (CL_r) of BMS-813160

End point title	Renal Clearance (CLr) of BMS-813160
End point description:	
CLr was calculated by dividing the total amount excreted in the urine from 0 to 6 hours by the area under the plasma concentration-time curve from time zero extrapolated to infinite time. The renal function was classified based on estimated glomerular filtration rate as normal (≥ 90 mL/min/1.73 m ²), mildly impaired (60-89 mL/min/1.73 m ²), moderately impaired stage 3A (45-59 mL/min/1.73 m ²), and moderately impaired stage 3B (30-44 mL/min/1.73 m ²). The analysis was planned to be performed in the Pharmacokinetic (PK) analysis set which included all subjects who receive a dose of study drug and have adequate PK concentration-time data.	
End point type	Secondary
End point timeframe:	
Pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose at Week 12	

End point values	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[8]	0 ^[9]	0 ^[10]	
Units: mL/min				
geometric mean (geometric coefficient of variation)	()	()	()	

Notes:

[8] - Data were not analysed due to the termination of development of BMS-813160.

[9] - Data were not analysed due to the termination of development of BMS-813160.

[10] - Data were not analysed due to the termination of development of BMS-813160.

Statistical analyses

No statistical analyses for this end point

Secondary: Dose-Response Relationship Using Change in Baseline Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment

End point title	Dose-Response Relationship Using Change in Baseline Urinary Albumin-to-Creatinine Ratio (UACR) Across 12 Weeks of Treatment
End point description:	
The presence of albumin in the urine (macroalbuminuria) is a marker of kidney disease. Albumin and creatinine concentrations were obtained from spot urine samples. UACR was calculated as the geometric mean of two first-morning void urine UACR measurements with samples collected on two separate occasions within a 4-day period. The effect of BMS-813160 on urinary albumin excretion as measured by UACR values in subjects with diabetic kidney disease after 12 weeks of treatment was assessed. The model included treatment group as a main effect, and the log of baseline UACR values, as well as baseline values of eGFR, blood pressure, blood glucose and lipid levels, as covariates. The analysis was planned to be performed in all the subjects who received any study treatment.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 8 and 12	

End point values	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	0 ^[11]	0 ^[12]	0 ^[13]	
Units: Percent change				
geometric mean (confidence interval 90%)	(to)	(to)	(to)	

Notes:

[11] - Data were not analysed due to the termination of development of BMS-813160.

[12] - Data were not analysed due to the termination of development of BMS-813160.

[13] - Data were not analysed due to the termination of development of BMS-813160.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

On-treatment non-serious adverse events: After first dose of study medication during 12-week treatment period and within 3 days of last dose

On-treatment serious adverse events: After first dose of study medication during 12-week treatment period

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	18.0

Reporting groups

Reporting group title	BMS-813160 150 mg QD
-----------------------	----------------------

Reporting group description:

Subjects received BMS-813160 150 mg, capsule, orally once daily in Ante Meridiem (AM) and Placebo matching with BMS-813160, capsule, orally once daily in Post Meridiem (PM) for 12 weeks.

Reporting group title	BMS-813160 300 mg BID
-----------------------	-----------------------

Reporting group description:

Subjects received BMS-813160 300 mg capsules, orally, twice daily for 12 weeks.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received BMS-813160 matching placebo capsules, orally, twice daily for 12 weeks.

Serious adverse events	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 29 (10.34%)	3 / 30 (10.00%)	1 / 29 (3.45%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
B-cell lymphoma			
subjects affected / exposed	1 / 29 (3.45%)	0 / 30 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial occlusive disease			
subjects affected / exposed	0 / 29 (0.00%)	1 / 30 (3.33%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina pectoris			

subjects affected / exposed	0 / 29 (0.00%)	0 / 30 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery occlusion			
subjects affected / exposed	0 / 29 (0.00%)	0 / 30 (0.00%)	1 / 29 (3.45%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	1 / 29 (3.45%)	0 / 30 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	1 / 29 (3.45%)	0 / 30 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 29 (0.00%)	1 / 30 (3.33%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Skin and subcutaneous tissue disorders			
Eczema			
subjects affected / exposed	1 / 29 (3.45%)	0 / 30 (0.00%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Lobar pneumonia			
subjects affected / exposed	0 / 29 (0.00%)	1 / 30 (3.33%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			

subjects affected / exposed	0 / 29 (0.00%)	1 / 30 (3.33%)	0 / 29 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	BMS-813160 150 mg QD	BMS-813160 300 mg BID	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 29 (10.34%)	2 / 30 (6.67%)	4 / 29 (13.79%)
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	1 / 29 (3.45%)	2 / 30 (6.67%)	3 / 29 (10.34%)
occurrences (all)	1	2	3
Fatigue			
subjects affected / exposed	3 / 29 (10.34%)	1 / 30 (3.33%)	1 / 29 (3.45%)
occurrences (all)	3	1	1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 January 2013	The main purpose of this amendment was to clarify the urine albumine-to-creatinine ratio (UACR) screening stratification requirements and the pharmacokinetic/pharmacodynamic collection schedule for subjects who discontinue early.
29 July 2013	The main purpose of this amendment was to update the inclusion and exclusion criteria, clinical procedures and lab test assessments.
11 November 2013	The main purpose of this amendment was to implement clinical and operational changes to aid sites in the execution of study.
09 July 2014	The main purpose of this amendment was to implement clinical and operational changes to aid sites in the execution of study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported